One of the biggest advantages of the Moderna vaccine is that it does not need to be stored extremely cold like the Pfizer vaccine group also in the US. Therefore, it will be easier to store and distribute. This gives hope to the world in the fight against Covid-19.
According to Stephane Bancel, President and CEO of Moderna pharmacy, the company’s Covid-19 vaccine has demonstrated safety in ongoing research, reaching 94.5% effective in preventing the SARS-CoV-2 virus and vaccinated people did not have any serious illness, which is definitely a pandemic-changing remedy.
Bancel said that if vaccines get emergency approval from the US Food and Drug Administration, Moderna will work with the Agency and the Centers for Disease Control and Prevention to deliver vaccines to people at high risk: “We have an agreement to order 100 million doses from the US government. We plan to produce about 20 million doses of Covid-19 vaccine for the US this year, in which millions of doses have been manufactured and are ready to be used as soon as they are approved by the Food and Drug Administration (FDA) “.
If further trials show that the vaccine is safe for students and young people to be vaccinated next summer, he stressed, the world may return to “normal life” for the school year in the fall of 2021.
Thus, within a week, Moderna became the second US pharmaceutical corporation to report the results of testing Covid-19 vaccine with higher effectiveness than forecast. Previously, vaccines Covid-19 of the company Pfizer (USA) and BioNTech (Germany) jointly developed it to be more than 90% effective. One advantage of the Covid-19 vaccine made by Moderna, however, is that the vaccine does not require the ultra-cold storage mode as the Pfizer vaccine, so it is easier to distribute.
Up to now, over 55 million people have been infected with Covid-19 in the world, more than 1.3 million people have died from this pandemic. Although Moderna claims its vaccine is 94.5% effective, according to World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, it is not subjective to stop the pandemic.
“This is not the time to be complacent. While we continue to receive encouraging news about the Covid-19 vaccine and remain cautiously optimistic about the potential for new vaccines to begin rolling out in In the coming months, we are extremely concerned about the increase in Covid-19 cases in many regions of the world, especially in Europe and the Americas, leaving the health system in a state of Overload”.
According to the World Health Organization, as of early October, experts around the world have researched and developed 193 Covid-19 vaccines, of which 42 are being clinically tested. Currently, a number of other countries such as China and Russia are stepping up the testing of the Covid-19 vaccine and starting to use it. Russia licensed a vaccine called Sputnik V in August this year for domestic use. On November 11, Russia said that Sputnik V achieved 92% preventive efficacy in clinical trials …